Androgen Receptor (AR) is essential for the growth and progression of prostate cancer in both hormone-sensitive and hormone-refractory disease. A DNA binding polyamide that targets the consensus androgen response element (ARE) binds the PSA promoter ARE, inhibits androgen-induced expression of PSA and several other ARregulated genes in cultured prostate cancer cells, and reduces AR occupancy at the PSA promoter and enhancer. Down-regulation of PSA by this polyamide was comparable to that produced by the synthetic anti-androgen bicalutamide (Casodex) at the same concentration. Genome-wide expression analysis reveals that a similar number of transcripts are affected by treatment with the polyamide and with bicalutamide. Direct inhibition of the AR-DNA interface by sequence-specific DNA binding small molecules could offer an alternative approach to antagonizing AR activity.
Introduction
The androgen receptor (AR) is a member of the ligand-activated nuclear receptor The regulation of prostate specific antigen (PSA, KLK3) expression by AR has been extensively studied as a model for AR mediated gene activation (4) (5) (6) (7) . Androgenic induction of PSA is mediated by AR binding to the proximal promoter approximately 170 base pairs from the transcription start site, and to several low-affinity AREs in an enhancer approximately 4000 base pairs upstream (4) (5) (6) . AREs in both the promoter and enhancer are important for induction after androgen stimulation. AR occupies both the promoter and enhancer regions and recruits transcriptional coactivators including p160 and p300, TATA binding protein, mediator, and RNA polymerase II to form the AR transcription complex (7, 8) . Chromatin capture assays suggest that the PSA enhancer is located near the promoter in this complex (8) .
AR signaling regulates normal prostate development and contributes to the progression of prostate cancer (9) . Surgical or drug therapies that act to limit circulating androgen levels or directly antagonize ligand binding to AR initially slow prostate cancer growth (10, 11) . However, nearly all patients treated with anti-androgen therapies will eventually develop hormone-refractory disease (12) . Dysregulation of AR activity ( Figure 5 .2), together with activation of the PTEN/AKT pathway, is thought to contribute to this transition (13) . Up-regulation of AR mRNA was found to occur in all transitions from hormone-sensitive to hormone-refractory disease in a mouse tumor-xenograft model of prostate cancer (14) . Additionally, a transgenic mouse with a mutated AR that inappropriately interacts with transcriptional co-regulators developed metastatic neoplastic disease (15) . Mutations in the AR ligand binding domain can render antagonists such as bicalutamide or flutamide ineffective, or in some models of hormonerefractory disease convert them to agonists (14, 16) . Since genotropic AR activity is thought to be necessary throughout prostate cancer progression, direct antagonism of AR:DNA binding could inhibit androgen receptor activity in hormone-refractory conditions where androgen antagonists that target the ligand-binding pocket are ineffective (9) . DNA binding polyamides represent one approach to inhibiting protein-DNA interactions. Polyamides containing N-methylimidazole (Im) and N-methylpyrrole (Py) comprise a class of programmable DNA-binding ligands capable of binding to a broad repertoire of DNA sequences with affinities and specificities comparable to those of natural DNA-binding proteins (17, 18) . Sequence specificity is programmed by side-byside pairings of the heterocyclic amino acids in the minor groove of DNA: Im/Py distinguishes G•C from C•G; Py/Py binds both A•T and T•A (19, 20) . Previously, a hairpin polyamide targeted to the hypoxia response element (HRE) inhibited hypoxia induced expression of several HIF-1 regulated genes including VEGF in cultured cells (21, 22 ). In this study we have designed a cell permeable polyamide to target the sequence The response of cultured prostate cancer cells to androgen has been extensively studied (23, 25) . We find that DHT induced the expression of a set of 199 transcripts by at least 4-fold (p ≤ 0.01) (Appendix B, Table B1 ). Of this set, 70 were also inhibited by polyamide 1 by at least 2-fold (p ≤ 0.01) (Appendix B, Table B2 ). 
-42.9 -36.4 -3.1 1.5 Table 5 .2 Fold-changes of selected AR-target genes relative to DHT-induced controls.
Discussion
Because numerous signaling pathways converge on a smaller number of transcription factors to exert their effects on gene expression, it has been proposed that transcription factors could be among the most appropriate drug targets in oncology (28, 29) . This has underscored the challenge to design small molecules capable of selectively disrupting protein-protein interactions between co-activators as well as protein-DNA interactions between transcription factors and their target sites in gene regulatory sequences.
Prostate cancer cells are dependent on stimulation by circulating androgens that exert their effects through the androgen receptor signaling axis. Hormone therapies that block AR activity by starving it of androgens or inhibiting ligand binding are initially successful but ultimately fail to control disease (12) . This can occur through up-regulation of AR, mutations in the ligand binding pocket, and ligand-independent activation from upstream signaling proteins (13, 30, 31) . It is thought, however, that intact activity of AR signaling is necessary for disease progression (9) . Inhibition of the AR-DNA interaction by a sequence-specific DNA binding molecule could be expected to interfere with AR signaling under both hormone-sensitive and refractory conditions. 
Methods
Synthesis of Polyamides. Polyamides 1 and 2 were synthesized by solid-phase methods on Kaiser oxime resin (Nova Biochem) according to established protocols (43) .
Polyamides were cleaved from resin with 3,3'-diamino-N-methyl-dipropylamine and purified by reverse-phase HPLC. Isophthalic acid was activated with PyBOP (Nova Biochem) and conjugated to the polyamides as previously described (22 When appropriate, bicalutamide was added two hours prior to DHT stimulation.
Isolation of RNA and cDNA synthesis were as previously described (21) . Quantitative real-time RT-PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems) on an ABI 7300 instrument. PSA mRNA was measured relative to ß-glucuronidase as an endogenous control. Primer sequences are available upon request.
Cell culture supernatants were collected for an ELISA (R&D Systems) to measure PSA protein according to the manufacturer's protocol.
Chromatin Immunoprecipitation. LNCaP cells were plated in 15 cm diameter plates at a density of 2 x 10 6 cells per plate. Media, polyamide treatment, time course, and DHT stimulation were the same as described above. After the 16 hour DHT treatment, cells were treated with 1% formaldehyde for 10 minutes. Chromatin was isolated and sheared.
Antibodies to AR (AR-20, Santa Cruz Biotechnology) were used to immunoprecipitate AR-bound DNA fragments. Crosslinks were reversed and PCRs using primers targeted to the regions of interest were used to assess enrichment of bound fragments as compared to mock-precipitated (no antibody) controls. PCRs were monitored using SYBR Green PCR Master Mix (Applied Biosystems) on an ABI 7300 instrument. Primer sequences and a more detailed experimental protocol are available upon request. See Appendix C for a more detailed protocol. 
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